Inventor · disambiguated record
Gunasekaran Kannan
Also filed as: KANNAN GUNASEKARAN
40 granted patents·26 pending applications·771 citations·filing 2009–2025
98Inventor score
Files withAMGEN INC44DENALI THERAPEUTICS INC12KANNAN GUNASEKARAN4NUTCRACKER THERAPEUTICS INC4LI YANG1
Top patents by PatentIndex Score
66 records- 0197US10093711B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2016·Granted Oct 9, 2018·25 cites·5 claims
- 0297US9580486B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2014·Granted Feb 28, 2017·47 cites·27 claims
- 0397US9546203B2Aglycosylated Fc-containing polypeptides with cysteine substitutionsAMGEN INC·Filed 2014·Granted Jan 17, 2017·34 cites·5 claims
- 0496US9932380B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2017·Granted Apr 3, 2018·23 cites·23 claims
- 0596US9243058B2BCMA antigen binding proteinsAMGEN INC·Filed 2013·Granted Jan 26, 2016·83 cites·26 claims
- 0696US8592562B2Method for making antibody Fc-heterodimeric molecules using electrostatic steering effectsKANNAN GUNASEKARAN·Filed 2009·Granted Nov 26, 2013·339 cites·18 claims
- 0795US9200060B2Monomeric antibody FcKANNAN GUNASEKARAN·Filed 2010·Granted Dec 1, 2015·46 cites·10 claims
- 0894US10829535B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2018·Granted Nov 10, 2020·5 cites·5 claims
- 0994US10220090B2BCMA Antigen binding proteinsAMGEN INC·Filed 2015·Granted Mar 5, 2019·15 cites·17 claims
- 1092US10851144B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2016·Granted Dec 1, 2020·16 cites·10 claims
- 1192US9862752B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2014·Granted Jan 9, 2018·16 cites·27 claims
- 1292US9714276B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2013·Granted Jul 25, 2017·17 cites·18 claims
- 1391US11884944B2Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereofDENALI THERAPEUTICS INC·Filed 2022·Granted Jan 30, 2024·2 cites·39 claims
- 1491US11541103B2Interleukin-21 mutein/ anti-PD-1 antibody conjugatesAMGEN INC·Filed 2018·Granted Jan 3, 2023·7 cites·34 claims
- 1591US10562950B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2018·Granted Feb 18, 2020·5 cites·12 claims
- 1691US10336798B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2017·Granted Jul 2, 2019·9 cites·21 claims
- 1790US10894814B2Growth differentiation factor 15 (GDF-15) constructsAMGEN INC·Filed 2017·Granted Jan 19, 2021·4 cites·25 claims
- 1889US11643446B2Progranulin variantsDENALI THERAPEUTICS INC·Filed 2022·Granted May 9, 2023·4 cites·50 claims
- 1989US10934362B2Bi-specific anti-CGRP receptor/PAC1 receptor antigen binding proteins and uses thereofAMGEN INC·Filed 2015·Granted Mar 2, 2021·5 cites·43 claims
- 2088US9822173B2Heterodimeric immunoglobulinsAMGEN INC·Filed 2013·Granted Nov 21, 2017·10 cites·19 claims
- 2188US9308258B2Stable and aggregation free antibody FC molecules through CH3 domain interface engineeringKANNAN GUNASEKARAN·Filed 2010·Granted Apr 12, 2016·13 cites·17 claims
- 2288US2024327485A1Interleukin-2 muteins for the expansion of t-regulatory cellsAMGEN INC·Filed 2024·Application pending·0 cites
- 2387US12102675B2MRNA therapeutic compositionsNUTCRACKER THERAPEUTICS INC·Filed 2024·Granted Oct 1, 2024·0 cites·17 claims
- 2487US12011478B2MRNA therapeutic compositionsNUTCRACKER THERAPEUTICS INC·Filed 2023·Granted Jun 18, 2024·0 cites·19 claims
- 2587US11518808B2Anti-PD-1 antibodies and methods of treatmentAMGEN INC·Filed 2019·Granted Dec 6, 2022·5 cites·21 claims
- 2686US11492417B2Proteins specific for BAFF and B7RP1 and uses thereofAMGEN INC·Filed 2019·Granted Nov 8, 2022·2 cites·6 claims
- 2786US10233237B2Heterodimeric immunoglobulinsAMGEN INC·Filed 2013·Granted Mar 19, 2019·8 cites·16 claims
- 2886US9458246B2Proteins specific for BAFF and B7RP1AMGEN INC·Filed 2014·Granted Oct 4, 2016·8 cites·16 claims
- 2985US2025082742A1Mrna therapeutic compositionsNUTCRACKER THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 3084US11739131B2Growth differentiation factor 15 (GDF-15) polypeptidesAMGEN INC·Filed 2019·Granted Aug 29, 2023·1 cites·6 claims
- 3184US10465009B2BCMA antigen binding proteinsAMGEN INC·Filed 2013·Granted Nov 5, 2019·9 cites·23 claims
- 3284US2024368236A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2024·Application pending·0 cites
- 3382US11104745B2Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereofAMGEN INC·Filed 2016·Granted Aug 31, 2021·5 cites·20 claims
- 3482US2025121046A1Mrna therapeutic compositionsNUTCRACKER THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 3581US11248052B2Antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptorAMGEN INC·Filed 2019·Granted Feb 15, 2022·1 cites·5 claims
- 3680US10421823B2Proteins specific for BAFF and B7RP1 and uses thereofAMGEN INC·Filed 2014·Granted Sep 24, 2019·2 cites·21 claims
- 3779US12479930B2Proteins specific for BAFF and B7RP1 and uses thereofAMGEN INC·Filed 2022·Granted Nov 25, 2025·0 cites·18 claims
- 3878US11198732B2Fc variantsAMGEN INC·Filed 2019·Granted Dec 14, 2021·1 cites·10 claims
- 3978US10421824B2Proteins specific for BAFF and B7RP1AMGEN INC·Filed 2016·Granted Sep 24, 2019·2 cites·13 claims
- 4078US2025367284A1Anti-transferrin receptor fusion proteins and methods of use thereofDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4178US2025387477A1Anti-transferrin receptor fusion proteins and methods of use thereofDENALI THERAPEUTICS INC·Filed 2025·Application pending·0 cites
- 4277US2024327486A1Interleukin-2 muteins for the expansion of t-regulatory cellsAMGEN INC·Filed 2024·Application pending·0 cites
- 4376US11976102B2Interleukin-2 muteins for the expansion of T-regulatory cellsAMGEN INC·Filed 2020·Granted May 7, 2024·0 cites·17 claims
- 4476US9574002B2Human antigen binding proteins that bind to a complex comprising β-Klotho and an FGF receptorLI YANG·Filed 2012·Granted Feb 21, 2017·2 cites·14 claims
- 4574US2023265137A1Progranulin variantsDENALI THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 4673US2024150736A1Fusion proteins comprising sulfoglucosamine sulfohydrolase enzymes and methods thereofDENALI THERAPEUTICS INC·Filed 2024·Application pending·0 cites
- 4770US2021079051A1Growth differentiation factor 15 (gdf-15) constructsAMGEN INC·Filed 2020·Application pending·0 cites
- 4870US2025325631A1Stabilization of fc-containing polypeptidesAMGEN INC·Filed 2025·Application pending·0 cites
- 4969US2022220172A1Progranulin variantsDENALI THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 5068US2023381276A1Interleukin-21 mutein/ anti-pd-1 antibody conjugatesAMGEN INC·Filed 2022·Application pending·0 cites
Showing the top 50 of 66 patent records by PatentIndex Score.
Join the waitlist — get patent alerts
Get an alert when Gunasekaran Kannan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →